Genmab (GMAB) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Genmab A/S, a prominent player in the medical research field, has announced plans to expand its share capital by up to DKK 6.6 million by 2029, offering new shares both with and without pre-emption rights for existing shareholders. The company is also issuing warrants to employees, excluding executive management, and introducing convertible debt instruments as part of its growth strategy, all aimed at enhancing flexibility in capital management. These steps are designed to support Genmab’s continued innovation and expansion in the biotech sector.
For further insights into GMAB stock, check out TipRanks’ Stock Analysis page.
